Dr. Dennis P. Morgan
Claim this profileUniversity of Mississippi Medical Center
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
11 reported clinical trials
19 drugs studied
Area of expertise
1Lung Cancer
Stage II
Stage III
Stage I
2Non-Small Cell Lung Cancer
Stage II
Stage III
Stage I
Affiliated Hospitals
Clinical Trials Dennis P. Morgan is currently running
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
More about Dennis P. Morgan
Clinical Trial Related6 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Dennis P. Morgan has experience with
- Pembrolizumab
- Talazoparib
- Carboplatin
- Paclitaxel
- Ramucirumab
- Gemcitabine Hydrochloride
Breakdown of trials Dennis P. Morgan has run
Lung Cancer
Non-Small Cell Lung Cancer
Thyroid Cancer
Relapse
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Dennis P. Morgan specialize in?
Dennis P. Morgan focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage II patients, or patients who are Stage III.
Is Dennis P. Morgan currently recruiting for clinical trials?
Yes, Dennis P. Morgan is currently recruiting for 4 clinical trials in Jackson Mississippi. If you're interested in participating, you should apply.
Are there any treatments that Dennis P. Morgan has studied deeply?
Yes, Dennis P. Morgan has studied treatments such as Pembrolizumab, Talazoparib, Carboplatin.
What is the best way to schedule an appointment with Dennis P. Morgan?
Apply for one of the trials that Dennis P. Morgan is conducting.
What is the office address of Dennis P. Morgan?
The office of Dennis P. Morgan is located at: University of Mississippi Medical Center, Jackson, Mississippi 39216 United States. This is the address for their practice at the University of Mississippi Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.